Endometrial mucinous adenocarcinoma

disease

On this page

Also known as endometrium mucinous adenocarcinomauterine mucinous carcinoma

Summary

Endometrial mucinous adenocarcinoma (MONDO:0002747) is a disease and 8 clinical trials. Top therapeutic interventions include cisplatin, nintedanib, and brivanib alaninate. A subtype of mucinous adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endometrial mucinous adenocarcinoma
Mondo ID	MONDO:0002747
EFO	EFO:1000236
DOID	DOID:3707
ICD-11	395055399
NCIT	C40144
UMLS	C1519859
MedGen	276939
Anatomy (UBERON)	UBERON:0001295
Is cancer (heuristic)	no

Also known as: endometrial mucinous adenocarcinoma · endometrium mucinous adenocarcinoma · uterine mucinous carcinoma

Disease family

This is a subtype of mucinous adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › mucinous adenocarcinoma › endometrial mucinous adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05112601	PHASE2	RECRUITING	Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT00492778	PHASE2	UNKNOWN	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00888173	PHASE2	COMPLETED	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887	PHASE2	COMPLETED	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01642082	PHASE2	COMPLETED	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01440998	PHASE1	COMPLETED	Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT05049538	Not specified	RECRUITING	Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1
NINTEDANIB	4	1
BRIVANIB ALANINATE	3	1
DALANTERCEPT	3	1

Drugs: Cisplatin, Nintedanib, Brivanib Alaninate, Dalantercept